Početna › Mijelofibroza › Kansas
Kliničke studije za Mijelofibroza u državi Kansas
6 studija za Mijelofibroza traži sudionike na lokacijama u državi Kansas.
Službeni tekst studije (engleski)
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
- University of Kansas Clinical Research Center, Fairway
- University of Kansas Cancer Center, Kansas City
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- i još 1
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 30. ruj 2026. · NCT06661915A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
- University of Kansas Medical Center, Kansas City
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 17. ruj 2026. · NCT06343805Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined
- The University of Kansas Cancer Center, Fairway
U tijeku regrutacijaRana faza 1Zdravi dobrovoljci dobrodošli
Od 18 godina i više · Oba spola · Ažurirano 6. svi 2026. · NCT06414681A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
- The University of Kansas Cancer Center, Westwood
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 17. tra 2026. · NCT06034002A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- University of Kansas Medical Center, Westwood
U tijeku regrutacijaFaza 2
Od 18 do 66 godina · Oba spola · Ažurirano 17. ožu 2026. · NCT06859424Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- University of Kansas Cancer Center - Westwood, Westwood
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2025. · NCT06479135Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.